Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Clin Cancer Res. 2013 Nov 27;20(3):525–527. doi: 10.1158/1078-0432.CCR-13-2636

Figure 1.

Figure 1

MET and VEGFR signaling in prostate cancer metastasis to bone. Prostate cancer cells, osteoblasts, and osteoclasts express the ligands and receptors HGF/MET and VEGF/VEGFR2, which may thus mediate autocrine and paracrine signaling in the bone metastatic niche. The balance of bone turnover between osteoblasts and osteoclasts is also mediated by RANK and RANK ligand (RANKL) activity. Expression of VEGF may also cause angiogenesis by signaling to VEGFRs on endothelial cells. Dual inhibition of MET and VEGFR2 pathways by cabozantinib may disrupt these signals, affecting prostate cancer “seed” and bone microenvironment “soil.”